Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Human Oral Nicotine Study, Hopes to Facilitate More Satisfying Experience with DehydraTECH(TM)-Processed Oral Nicotine
Lexaria recently reported that dosing of the targeted 36 volunteers in its human clinical oral nicotine study, NIC-H22-1, had been…